The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis

Expert Opinion on Drug Delivery

Volumn 4, Issue 4, 2007, Pages 389-402

  Gunn, Andrew J ^a,b   Brechbiel, Martin W ^b   Choyke, Peter L ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunoconjugates; Malignant peritoneal mesothelioma; Metastatic colorectal cancer; Metastatic gastric cancer; Metastatic ovatian cancer; Metastatic pancreatic cancer; Molecular imaging; Multi modality imaging; Peritoneal carcinomatosis; Photodynamic therapy; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ARCITUMOMAB TC 99M; AVIDIN; BISMUTH 212; BISMUTH 213; CALICHEAMICIN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CISPLATIN; COPPER 67; DEPREOTIDE TC 99M; DOXORUBICIN; FLUORESCENT DYE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM CHELATE; GELDANAMYCIN; IBRITUMOMAB TIUXETAN; IODINATED CONTRAST MEDIUM; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3 IN 111; MONOCLONAL ANTIBODY MUCIN 1; PENTETREOTIDE IN 111; POLYAMIDOAMINE; RHENIUM 186; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ADJUVANT THERAPY; BILE LEAKAGE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM CANCER; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; FEVER; FLUORESCENCE ANALYSIS; GAMMA SCINTIGRAPHY; GASTROINTESTINAL DISEASE; GYNECOLOGIC CANCER; HEMATOLOGIC DISEASE; HUMAN; HYPERTHERMIC THERAPY; INFECTION; INTESTINE FISTULA; LEUKOPENIA; MOLECULAR IMAGING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PANCREATITIS; PERITONEUM MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; RADIOIMMUNOTHERAPY; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; UNNECESSARY PROCEDURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; CONTRAST MEDIA; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC RESONANCE IMAGING; MICROSCOPY, FLUORESCENCE; PERITONEAL NEOPLASMS; PHOTOCHEMOTHERAPY; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 34547880790     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.4.389     Document Type: Review

References (78)

1. CHAN JK, CHEUNG MK, HUSAIN A et al.: Patterns and progress in ovarian cancer over 14 years. Obstet. Gynecol. (2006) 108(3 Part 1):521-528.
2. RIALL TS, NEALON WH, GOODWIN JS et al.: Pancreatic cancer in the general population: improvements in survival over the last decade. J. Gastrointest. Surg. (2006) 10(9):1212-1223.
3. GLEHENO, MOHAMED F, GILLY FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. (2004) 5(4):219-228.
4. ARCHER AG, SUGARBAKER PH, JELINEK JS: Radiology of peritoneal carcinomatosis. Cancer Treat. Res. (1996) 82:263-288.
5. GRIFFITHS CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. (1975) 42:101-104.
6. KOPPE MJ, BOERMAN OC, OYEN WJ, BLEICHRODT RP: Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann. Surg. (2006) 243(2):212-222.
7. LANGER CJ, ROSENBLUM N, HOGAN M et al.: Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother. Pharmacol. (1993) 32(3):204-208.
8. YONEMURA Y, KAWAMURA T, BANDOU E, TAKAHASHI S. SAWA T, MATSUKI N: Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br. J. Surg. (2005) 92(3):370-375.
9. FARMA JM, PINGPANK JF, LIBUTTI SK et al.: Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J. Gastrointest. Surg. (2005) 9(9):1346-1353.
10. CULLIFORD AT, BROOKS AD, SHARMA S et al.: Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann. Surg. Oncol. (2001) 8(10):787-795.
11. FELDMAN AL, LIBUTTI SK, PINGPANK JF et al.: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J. Clin. Oncol. (2003) 21(24):4560-4567.
12. FONG Y, SALDINGER PF, AKHURST T et al.: Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal carcinoma. Am. J. Surg. (1999) 178(4):282-287.
13. WIERING B, KRABBE F, JAGER GJ, OYEN WJ, RUERS TJ: The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer (2005) 104(12):2658-2670.
14. SUGARBAKER PH, KEM K, LACK E: Malignant pseudomyxoma peritonei of colonic origin. Natrual history and presentation of a curative approach to treatment. Dis. Colon Rectum (1987) 30(10):772-779.
15. HAHN GM: Potential for therapy of drugs and hyperthermia. Cancer Res. (1979) 39(6 Part 2):2264-2268.
16. MEYN RE, CORRY PM, FLETCHER SE, DEMETRIADES M: Thermal enhancement of DNA damage in mammalian cells treated with cis-diammi nedichlorplatinum(II). Cancer Res. (1980) 40(4):1136-1139.
17. ALBERTS DS, PENG YM, CHEN HS,MOON TE, CETAS TC, HOESCHELE JD:Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J. Natl. Cancer Inst. (1980) 65(2):455-461.
18. LOS G, VAN VUGT MJ, PINEDO HM: Response of peritonea] solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br. J. Cancer (1994) 69(2):235-241.
19. ELIAS D, BLOT F, EL OTMANY A et al.: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer (2001) 92(1):71-76.
20. BRIGAND C, MONNEUSE O, MOHAMED F et al.: Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results ala prospective study. Ann. Surg. Oncol. (2006) 13(3):405-412.
21. KOULOULIAS VE, NIKITA KS, KOUVARIS JR et al.: Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy. J. Hepatobiliary Pancreat. Surg. (2001) 8(6):564-570.
22. ARMSTRONG DK, BUNDY B, WENZEL L et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. (2006) 354(1):34-43.
23. ESQUIVEL J, VIDAL-JOVE J, STEVENS MA, SUGARBAKER PH: Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery (1993) 113(6):631-636.
24. GLEHEN O, OSINSKY D, COTTE E et al.: Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreduction surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann. Surg. Oncol. (2003) 10(8):863-869.
25. VERWAAL VJ, VAN TINTEREN H, RUTH SV, ZOETMULDER FA: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J. Surg. Oncol. (2004) 85(2):61-67.
26. SHARKEY RM, GOLDENBERG DM: Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin. (2006) 56(4):226-243.
27. OLAFSEN T, KENANOVA VE. SUNDARESAN G et al.: Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. (2005) 65(13):5907-5916.
28. KENANOVA V, OLAFSEN T, CROW DM et al.: Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. (2005) 65(2):622-631.
29. 213Bi-conjugated monoclonal antibody. Clin. Cancer Res. (2005) 11(19 Part 2):s7070-s7074.
30. BARANOWSKA-KORTYLEWICZ J, ABE M, NEARMAN J, ENKE CA: Emerging role of platelet-derived growth factor receptor-β inhibition in radioimmunotherapy of experimental pancreatic cancer. Clin. Cancer Res. (2007) 13(1):299-306.
31. 213Bi-CHX.A″-C595. Cancer Biol. Ther. (2005) 4(8):848-853.
32. 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int. J. Cancer (2004) 109(4):618-626.
33. ELGQVIST J, ANDERSSON H, BACK T et al.: α-Radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose. J. Nucl. Med. (2006) 47(8):1342-1350.
34. 90Y-DOTA]776. I on growth of OVCAR-3 ovarian carcinoma xenografts. Gynecol. Oncol. (2006) 102(3):462-467.
35. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol. Immunother. (2005) 54(12):1200-1213.
36. BORCHARDT PE, QUADRI SM, FREEDMAN RS, VRIESENDORP HM: Intraperitonea] radioimmunotherapy with human monoclonal IgM in nude mice with peritoneal carcinomatosis. Cancer Biother. Radiopharm. (2000) 15(1):53-64.
37. KINUYA S, YOKOYAMA K, FUKUOKA M et al.: Intraperitoneal radioimmunotherapy to treat the early phase peritoneal dissemination of human colon cancer cells in a murine model. Nucl. Med. Commun. (2007) 28(2):129-133.
38. KINUYA S, LI XF, YOKOYAMA K et al.: Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy. Cancer Sci. (2003) 94(7):650-654.
39. KOPPE MJ, HENDRIKS T, BOERMAN OC, OYEN WJ, BLEICHRODT RP: Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carinomatosis. J. Nucl. Med. (2006) 47(11):1867-1874.
40. KOPPE MJ, OEYN MJ, BLEICHRODT RP, VERHOFSTED AA, GOLDENBERG DM, BOERMAN OC: Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Biother. Radiopharm. (2006) 21(5):506-514.
41. KOBAYASHI H, KAWAMOT S, SAGA T et al.: Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. Bioconjug. Chem. (2001) 12(4):587-593.
42. GREEN NM: Avidin and streptavidin. Methods Enzymol. (1990) 184:51-67.
43. BLANKENBERG FG: Molecular imaging: the latest generation of contrast agents and tissue characterization techniques. J. Cell Biochem. (2003) 90(3):443-453.
44. ROSELLI M, MILENIC DE, BRECHBIEL MW et al.: In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. Cancer Biother: Radiopharm. (1999) 14(3):209-220.
45. CHAPPELL LL, DEAL KA, DADACHOVA E, BRECHBIEL MW: Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications. Bioconjug. Chem. (2000) 11(4):510-519.
46. CHAPPELL LL, MA D, MILENIC DE et al.: Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N, N′,N″,N‴-tetraacetic acid for radiolabeling proteins. Nucl. Med. Biol. (2003) 30(6):581-595.
47. 90Y using a bifunctional DTPA chelating agent. Cancer Biother. Radiopharm. (2003) 18(3):355-363.
48. CLIFFORD T, BOSWELL CA, BIDDLECOMBE GB, LEWIS JS, BRECHBIEL MW: Validation of a novel CHX-A″ derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A″-octreotide. J. Med. Chem. (2006) 49(14):4297-4304.
49. GOLDENBERG DM, DELAND F, KIM E et al.: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N. Engl. J. Med. (1978) 298(25):1384-1386.
50. MILENIC DE, ROSELLI M, BRECHBIEL MW et al.: In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand. Eur. J. Nucl. Med. (1998) 25(5):471-480.
51. SATO N, KOBAYASHI H, SAGA T et al.: Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin. Cancer Res. (2001) 7(11):3606-3612.
52. HAMA Y, URANO Y, KOYAMA Y et al.: In vivo spectral fluorescence imaging of submilliter peritoneal cancer implants using a lectin-targeted optical agent. Neoplasia (2006) 8(7):607-612.
53. HAMA Y, URANO Y, KOYAMA Y et al.: A target-cell specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-Rhodamine conjugate. Cancer Res. (2007) 67(6):2791-2799.
54. HAMA Y, URANO Y, KOYAMA Y, CHOYKE PL, KOBAYASHI H: Targeted optical imaging of cancer cells using lectin-binding BODIPY conjugated avidin. Biochem. Biophys. Res. Commun. (2006) 348(3):807-813.
55. HAMA Y, URANO Y, KOYAMA Y, CHOYKE PL, KOBAYASHI H: D-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamine-conjugated serum albumin-Rhodamine green. J. Biomed. Optics. (submitted).
56. YAO Z, ZHANG M, SAKAHARA H, SAGA T, ARANO Y, KONISHI J: Avidin targeting of intraperitoneal tumor xenografts. J. Natl. Cancer Inst. (1998) 90(1):25-29.
57. STOCKERT RJ: The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev. (1995) 75(3):591-609.
58. HYTONEN VP, LAITINEN OH, GRAPPUTO A et al.: Characterization of poultry egg-white avidins and their potential as a tool in pretargeting cancer treatment. Biochem. J. (2003) 372(Part 1):219-225.
59. PAGANELLI G, CHINOL M, MAGGIOLO M et al.: The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur. J. Nucl. Med. (1997) 24(3):350-351.
60. ACHILEFU S, JIMENEZ HN, DORSHOW RB et al.: Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J. Med Chem. (2002) 45(10):2003-2015.
61. BECKER A, HESSENIUS C, LICHA K et al.: Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat. Biotechnol. (2001) 19(4):327-331.
62. BECKER A, HESSENIUS C, BHARGAVA S et al.: Cyanine dye labeled vasoactive intestinal peptide and somatostatin analog for optical detection of gastroenteropancreatic tumors. Ann. NY Acad. Sci. (2000) 921:275-278.
63. WEISSLEDER R, TUNG CH, MAHMOOD U, BOGDANOV A: In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotech. (1999) 17(4):375-378.
64. SCHRAMA D, REISFELD RA, BECKER JC: Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. (2006) 5(2):147-159.
65. MANDLER R, KOBAYASHI H, HINSON ER, BRECHBIEL MW, WALDMANN TA: Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res. (2004) 64(4):1460-1467.
66. HAMANN PR, HINMAN LM, BEYER CF et al.: A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjug. Chem. (2005) 16(2):354-360.
67. VON MENSDORFF-POUILLY S, SNIJDEWINT FG, VERSTRAETEN AA, VERHEIJEN RH, KENEMANS P: Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Biol. Markers (2000) 15(4):343-356.
68. VAN HOF AC, MOLTHOFF CF, DAVIES Q: Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose. Cancer Res. (1996) 56(22):5179-5185.
69. CHAN SY, GORDON AN, COLEMAN RE et al.: A Phase II study of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol. Immunother. (2003) 52(4):243-248.
70. DENARDO SJ, DENARDO GL: Targeted radionuclide therapy for solid tumors: an overview. Int. J. Rad. Oncol. Biol. Phys. (2006) 66(2):S89-S95.
71. MILENIC DE, BRADY ED, BRECHBIEL MW: Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov. (2004) 3(6):488-499.
72. MILENIC DE, GARMESTANI K, BRADY ED et al.: α-Particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother. Radiopharm. (2005) 20(5):557-568.
73. BEHR TM, LIERSCH T, GREINER-BECHERT L et al.: Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer (2002) 94(Suppl. 4):1373-1381.
74. 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J. Clin. Oncol. (2005) 23(27):6763-6770.
75. 131I-chimerich TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother. Radiopharm. (2006) 21(3):243-256.
76. ALVAREZ RD, HUH WK, KHAZAELI MB et al.: A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. (2002) 8(9):2806-2811.
77. OEI AL, VERHEIJEN RH, SEIDEN MV et al.: Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int. J. Cancer (2007) 120(12):2710-2714.
78. TALANOV VS, REGINO CA, KOBAYASHI H, BERNARDO M, CHOYKE PL, BRECHBIEL MW: Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett. (2006) 6(7):1459-1463.